
Profitability, historical returns, and peer comparisons.
According to Ascentage Pharma Group International’s latest financial reports and current stock price. The company's current ROE is -153.78%. This represents a change of 23.76% compared to the average of -124.26% of the last 4 quarters.
The mean historical ROE of Ascentage Pharma Group International over the last ten years is -144.03%. The current -153.78% ROE has changed 6.77% with respect to the historical average. Over the past ten years (40 quarters), ASPHF's ROE was at its highest in in the December 2016 quarter at 202.85%. The ROE was at its lowest in in the December 2023 quarter at -866.12%.
Average
-144.03%
Median
-85.70%
Minimum
-1532.08%
Maximum
738.32%
Discovering the peaks and valleys of Ascentage Pharma Group International ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 609.12%
Maximum Annual ROE = 738.32%
Minimum Annual Increase = -587.13%
Minimum Annual ROE = -1532.08%
| Year | ROE | Change |
|---|---|---|
| 2025 | -91.36% | -40.46% |
| 2024 | -153.46% | -89.98% |
| 2023 | -1532.08% | 609.12% |
| 2022 | -216.05% | 240.95% |
| 2021 | -63.37% | -20.83% |
| 2020 | -80.04% | -51.87% |
| 2019 | -166.28% | -587.13% |
| 2018 | 34.14% | -62.04% |
| 2017 | 89.92% | -87.82% |
The current ROE of Ascentage Pharma Group International (ASPHF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-592.30%
5-year avg
-411.27%
10-year avg
-144.03%
Ascentage Pharma Group International’s ROE is less than InnoCare Pharma Limited (17.47%), greater than Zai Lab Limited (-31.11%), greater than CStone Pharmaceuticals (-43.54%), less than Edding Genor Group Holdings Limited (10.99%), less than Jacobio Pharmaceuticals Group Co., Ltd. (47.76%), less than Lepu Biopharma Co., Ltd. (17.36%), less than HUTCHMED (China) Limited (1.43%), less than Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (2.43%), greater than Alphamab Oncology (-10.27%), greater than TYK Medicines, Inc (-77.60%),
| Company | ROE | Market cap |
|---|---|---|
| 17.47% | $15.04B | |
| -31.11% | $20.46B | |
| -43.54% | $9.02B | |
| 10.99% | $3.13B | |
| 47.76% | $3.14B | |
| 17.36% | $4.35B | |
| 1.43% | $18.29B | |
| 2.43% | $95.23B | |
| -10.27% | $4.95B | |
| -77.60% | $1.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascentage Pharma Group International using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascentage Pharma Group International or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Ascentage Pharma Group International's ROE?
How is the ROE calculated for Ascentage Pharma Group International (ASPHF)?
What is the highest ROE for Ascentage Pharma Group International (ASPHF)?
What is the 3-year average ROE for Ascentage Pharma Group International (ASPHF)?
What is the 5-year average ROE for Ascentage Pharma Group International (ASPHF)?
How does the current ROE for Ascentage Pharma Group International (ASPHF) compare to its historical average?